[1]Patent:EP2105442,2009,A1,.Locationinpatent:Page/Pagecolumn13
[2]Patent:CN108276396,2018,A,.Locationinpatent:Paragraph0041;0052;0053;0068;0083
[3]BioorganicandMedicinalChemistry,2012,vol.20,#10,p.3263-3279
[4]Patent:EP2009010,2008,A1,.Locationinpatent:Page/Pagecolumn6-7
[1]Patent:EP2105442,2009,A1,.Locationinpatent:Page/Pagecolumn15
[2]Patent:CN107459500,2017,A,.Locationinpatent:Paragraph0024;0025
[1]Patent:CN105541816,2016,A,.Locationinpatent:Paragraph0032;0033;0034
[1]BioorganicandMedicinalChemistry,2012,vol.20,#10,p.3263-3279
[2]BeilsteinJournalofOrganicChemistry,2017,vol.13,p.1064-1070
[3]Patent:CN108276396,2018,A,
[1]BeilsteinJournalofOrganicChemistry,2017,vol.13,p.1064-1070
[2]BeilsteinJournalofOrganicChemistry,2017,vol.13,p.1064-1070
[1]Patent:CN108276396,2018,A.Locationinpatent:Paragraph0041;0070;0085;0054;0055
[2]BeilsteinJournalofOrganicChemistry,2017,vol.13,p.1064-1070
[3]Patent:EP2009010,2008,A1.Locationinpatent:Page/Pagecolumn7
[1]Patent:EP2105442,2009,A1.Locationinpatent:Page/Pagecolumn13
[2]Patent:CN108276396,2018,A.Locationinpatent:Paragraph0041;0052;0053;0068;0083
[3]BioorganicandMedicinalChemistry,2012,vol.20,p.3263-3279
[4]Patent:EP2009010,2008,A1.Locationinpatent:Page/Pagecolumn6-7
[1]Patent:EP2105442,2009,A1.Locationinpatent:Page/Pagecolumn15
[2]Patent:CN107459500,2017,A.Locationinpatent:Paragraph0024;0025
Title: Pharmacological aspects of the safety of gliflozins.
Journal: Pharmacological research 20170401
Title: Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.
Journal: Journal of diabetes investigation 20160501
Title: Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Journal: Clinical pharmacokinetics 20150701
Title: No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
Journal: Diabetes, obesity & metabolism 20121001
Title: Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Journal: Clinical therapeutics 20120801
Title: Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Journal: Bioorganic & medicinal chemistry 20120515
Title: Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Journal: Naunyn-Schmiedeberg's archives of pharmacology 20120401
Title: Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
Journal: Journal of pharmacological sciences 20120101
Title: Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
Journal: Diabetes technology & therapeutics 20111201
Title: Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
Journal: Clinical drug investigation 20111201
